[Modification of the radiation effects for overcoming radiation-resistant hypoxic tumor tissue].
D004999:Amifostine / Q000627:therapeutic use; D000818:Animals; D002493:Central Nervous System Diseases / Q000139:chemically induced; D004285:Dogs; D006801:Humans; D006979:Hyperthermia, Induced; D066298:In Vitro Techniques; D007422:Intestines / Q000528:radiation effects; D008214:Lymphocytes / Q000187:drug effects; D008795:Metronidazole / Q000627:therapeutic use; D051379:Mice; D008920:Misonidazole / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000532:radiotherapy*; D009417:Nerve Tissue / Q000187:drug effects / Q000528:radiation effects; D009574:Nitro Compounds / Q000627:therapeutic use; D010100:Oxygen / Q000378:metabolism; D011829:Radiation Dosage; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D051381:Rats
D009574:Nitro Compounds; D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents; D008795:Metronidazole; D008920:Misonidazole; D004999:Amifostine; D010100:Oxygen
Modifikation der Strahlenwirkung zur Uberwindung der Strahlenresistenz hypoxischer Tumoranteile.